Related Experiment Video
Updated: Jun 5, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression
Borna Relja1, Frank Meder, Minhong Wang
1Department of Trauma, Hand and Reconstructive Surgery, Hospitals of the Goethe-University Frankfurt am Main, 60590 Frankfurt, Germany. info@bornarelja.com
Insights
Simvastatin, a cholesterol-lowering drug, inhibits hepatocellular carcinoma (HCC) cell growth and adhesion by reducing key cell adhesion molecules and Rho-dependent kinase (ROCK) activity. These findings suggest simvastatin as a potential novel treatment for HCC.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Hepatocellular carcinoma (HCC) is a major global health concern and a leading cause of cancer mortality.
- Simvastatin, a 3-hydroxy-3-methyl-glutarylcoenzyme-A (HMG-CoA) reductase inhibitor, has demonstrated potential anticancer properties.
- The precise mechanism of simvastatin's action in HCC remains incompletely understood.
Purpose of the Study:
- To investigate the effects of simvastatin on HCC cell growth and adhesion.
- To elucidate the underlying mechanism of simvastatin's action in HCC.
- To evaluate the role of integrins and Rho-dependent kinase (ROCK) in simvastatin's anti-cancer effects.
Main Methods:
- HepG2 and Huh7 HCC cell lines were treated with simvastatin.
- Cell proliferation was assessed using the MTT assay.
- Cell adhesion to endothelial cells, integrin expression (ß1, ß3, α2), and ROCK pathway activation (ROCK-I, p-MYPT) were analyzed via Western blot and blocking studies.
Main Results:
- Simvastatin significantly inhibited HCC cell growth and adhesion to endothelium in a dose-dependent manner.
- Simvastatin treatment led to decreased expression of ß1, ß3, and α2 integrins.
- Simvastatin reduced ROCK-I expression and MYPT activation, and ROCK inhibition mimicked simvastatin's anti-adhesive effects.
Conclusions:
- Simvastatin exerts anti-cancer effects in HCC by modulating cell adhesion molecules and inhibiting the ROCK pathway.
- These findings highlight simvastatin's potential as a novel therapeutic agent for hepatocellular carcinoma.
- The study identifies specific molecular targets and pathways involved in simvastatin's anti-HCC activity.
Abstract:
Hepatocellular carcinoma (HCC) has become a global health concern and is one of the leading causes of cancer death after lung and gastric cancers. It has been suggested that the 3-hydroxy-3-methyl-glutarylcoenzyme-CoA (HMG-CoA) reductase inhibitor simvastatin exhibits anticancer properties. To this end, we analyzed the influence of simvastatin on the cell growth and adhesion of HCC and evaluated the yet poorly characterized mechanism of action of simvastatin in HCC. HepG2 and Huh7 cells were treated with simvastatin (16-64 μM) for different time periods. Cell proliferation using the MTT assay and tumor cell adhesion to endothelial cell monolayers were evaluated. ß1, ß3 and α2 integrin adhesion receptors and the downstream target of simvastatin Rho-dependent kinase (ROCK) were analyzed by Western blot. Further blocking studies with the ROCK-inhibitor H1152 and anti-integrin ß1 and ß3 antibodies were carried out. Simvastatin treatment inhibited dose-dependently tumor cell growth and attachment to endothelium. The inhibitory effect of simvastatin on cell adhesion was associated with decreased expression of ß1, ß3 and α2 integrins. Furthermore, simvastatin strongly reduced the expression of ROCK-I and activated MYPT, an indicator of ROCK activity. Also, the ROCK-inhibitor H1152 reduced the adhesive capacity of the tumor cells. Anti-adhesive effects of simvastatin were prevented by exogenous mevalonate, a downstream product of HMG-CoA. Tumor cell adhesion to endothelium was significantly impaired following incubation with functional anti-ß1 antibody. Simvastatin modifies the expression of cell adhesion molecules leading to reduced tumor cell growth and invasion. These beneficial effects of simvastatin may be mediated by ROCK. The data presented may point to novel treatment options for HCC.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions
Some...
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
